On September 4, 2025 GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager TriKE platform, reported that Michael Breen, Executive Chairman and Chief Executive Office of GT Biopharma, will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 in New York City (Press release, GT Biopharma, SEP 4, 2025, https://ir.gtbiopharma.com/news/detail/298/gt-biopharma-to-participate-in-the-h-c-wainwright-27th-annual-global-investment-conference [SID1234655765]). Investors interested in scheduling a one-on-one meeting can contact their H.C. Wainwright representative.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 27th Annual Global Investment Conference – September 8-10, 2025
An on-demand webcast of the Company’s presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, through the webcast link below as well as on the Company’s IR Calendar webpage.
Webcast link: View Source